2. TGF-beta/Smad Apoptosis Immunology/Inflammation Cytoskeleton
  3. TGF-β Receptor Apoptosis Interleukin Related Integrin Cadherin
  4. THR-123

THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

THR-123

THR-123 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

THR-123 Related Antibodies

Top Publications Citing Use of Products

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All Integrin Isoform Specific Products:

View All Isoforms
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis[1].

IC50 & Target[1]

BMPR1A

 

IL-6

 

IL-8

 

In Vitro

THR-123 (0-100 μM, 60 min) inhibits the expression of IL-6, IL-8 and ICAM-1 induced by TNF-α in a concentration-dependent manner in HK-2 cells[1].
THR-123 (250 μM) significantly inhibits TGF-β1, hypoxia, or cisplatin-induced cell apoptosis in HK-2 cells[1].
THR-123 (10 μM) restores the expression of E-cadherin inhibited by TGF-β1, reduces the expressions of CTGF and Snail1, and reverses the transformation of cell morphology into the mesenchymal form[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

THR-123 Related Antibodies
In Vivo

THR-123 (5 mg/kg, p.o., once daily for 3 weeks) reverses renal fibrosis in mice with nephrotoxic serum-induced chronic kidney fibrosis (NTN)[1]. THR-123 (5 mg/kg, p.o., once daily for 7 days) significantly reduces renal tubular necrosis and tissue damage in ischemic re-perfusion injury (IRI) model in mice[1].
THR-123 (5-15 mg/kg, p.o. or i.p., once daily for 5-7 days) inhibits interstitial volume expansion and collagen deposition in unilateral ureteral obstruction (UUO) model in mice[1].
THR-123 (5 mg/kg, p.o., once daily from 8 weeks to 16 weeks of age) does not alter the glomerular abnormalities, and significantly inhibits the tubular atrophy and interstitial fibrosis seen in COL4A3KO mice[1].
THR-123 (5 mg/kg, p.o., once daily for 3 months) inhibits the progression of fibrosis associated with advanced diabetic nephropathy in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nephrotoxic serum nephritis, NTN model established in CD1 mice[1]
Dosage: 5 mg/kg
Administration: Oral administration (p.o.), once daily for 3 weeks
Result: Significantly reversed the already formed renal fibrosis, and improve glomerular sclerosis, renal tubular atrophy and interstitial fibrosis.
Significantly reduced renal function indicators.
Inhibited epithelial-mesenchymal transition (EMT) and reduce the number of E-cadherin and FSP1 double-positive renal tubular cells.
Reduced macrophage infiltration and activate the BMP-Smad signaling pathway (p-Smad1/5).
Animal Model: IRI model established in C57Bl/6 mice (8 weeks)[1]
Dosage: 5 mg/kg
Administration: Oral administration (p.o.), once daily for 7 days
Result: Significantly reduced the proportion of renal tubular necrosis and lowered the blood urea nitrogen level.
Reduced macrophage infiltration and alleviated cell apoptosis.
Animal Model: UUO model established in CD1 mice (8-12 week)[1]
Dosage: 5 and 15 mg/kg (p.o.) or 5 mg/kg (i.p.)
Administration: Oral administration (p.o.) or intraperitoneal injection (i.p.), once daily for 5-7 days
Result: Inhibited interstitial volume expansion and collagen deposition.
Reduced the expression of fibrosis markers (fibronectin and type I collagen).
Animal Model: Alport syndrome model established in eight weeks-old COL4A3KO mice on C57Bl/6 background[1]
Dosage: 5 mg/kg
Administration: Oral administration (p.o.), once daily from 8 weeks of age to 16 weeks of age
Result: Improved glomerular sclerosis, tubular damage and interstitial fibrosis.
Restored the expression of E-cadherin and reduce the fibroblast marker FSP1.
Animal Model: Streptozotocin (HY-13753) induced Diabetic nephropathy, DN model established in male CD1 mice (8 week)[1]
Dosage: 5 mg/kg
Administration: Oral administration (p.o.), once daily for 3 months
Result: Reduced mesangial matrix expansion, macrophage infiltration and cell apoptosis.
Delayed the deterioration of renal function in combination of Captopril (HY-B0368).
Molecular Weight

1926.13

Formula

C83H124N22O27S2
Sequence

Cys-Tyr-Phe-Asp-Asp-Ser-Ser-Asn-Val-Leu-Cys-Lys-Lys-Tyr-Arg-Ser (disulfide bridge: Cys1-Cys11)
Sequence Shortening

CYFDDSSNVLCKKYRS (disulfide bridge: Cys1-Cys11)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

THR-123 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

THR-123THR123THR 123TGF-β ReceptorApoptosisInterleukin RelatedIntegrinCadherinTransforming growth factor beta receptorsILRenal FibrosisBMP SignalingEpithelial-to-Mesenchymal Transition (EMT)RegenerationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
THR-123
Cat. No.:
HY-P11354
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.